Search
Memorial Sloan Kettering Cancer Center (MSK) announced today that Ross Levine, MD, has been named MSK’s new Chief Scientific Officer (CSO). A renowned physician-scientist, Dr. Levine previously served as Senior Vice President of Translational Research in Memorial Hospital (MH) and holds the Edward P. Evans Endowed Chair for Myelodysplastic Syndromes at MSK.
In response to the intense fear that so many people experience around imaging tests, MSK radiology nurses developed new recommendations that are helping patients everywhere.
Learn how people with cancer can reduce insomnia during and after treatment.
A team of experts at Memorial Sloan Kettering shared their insights on colorectal cancer and general digestive health in an Information Session for patients, caregivers and those at increased risk for the disease.
Two new therapy options have demonstrated significant advances in survival outcomes for select patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Both studies were presented today at the 2025 ASCO Annual Meeting in Chicago and simultaneously published in The New England Journal of Medicine.
New MSK research identifies a rare cell population responsible for AML persistence and resistance to therapy; sheds new light on early brain development; and investigates how other health conditions can increase cancer risk in midlife. MSK clinical trials also supported the recent approval of the targeted drug larotrectinib by the FDA.
A recent Memorial Sloan Kettering study shows that some circulating tumor cells can circle back and infiltrate their tumor of origin, enhancing its growth and aggressiveness.
If you think women are the only people who get cancers caused by the human papillomavirus (HPV), think again. These cancers are on the rise in men.
Dr. Mao leads a team of integrative medicine specialists who offer complementary therapies such as massage and acupuncture to patients and caregivers.
A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal residual disease (MRD) responses compared to VRd alone in patients with newly diagnosed, transplant-ineligible multiple myeloma.